DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) met with the U.S. Food and Drug Administration (FDA) in late September 2006 to continue ongoing discussions related to Inspire’s dry eye clinical program for Prolacria™ (the proposed U.S. trade name for diquafosol tetrasodium ophthalmic solution 2%).
